# Novartis's $2B Deal Targets the Tolerability Problem That Limits Every PI3K Cancer Drug

- slug: novartiss-2b-deal-targets-the-tolerability-problem-that-limits-every-pi3k-cancer-drug
- date: 2026-03-20
- category: Biotech & Life Sciences

Novartis is acquiring a PI3Kα inhibitor from Synnovation Therapeutics that is designed to spare normal cells — addressing the tolerability problem that has limited this drug class in solid tumors.

---